Oral EP262 Fails to Beat Placebo in Urticaria Trial
A Phase II study of the oral MRGPRX2 blocker EP262 for chronic spontaneous urticaria did not show a significant advantage over placebo.
Global Allergies News
Allergies in the world runs on seasonal conditions, food allergies, anaphylaxis, research studies, treatment advances and public health guidance, and coverage here follows all of it. Reporting spans developments in medical research, policy adjustments and safety alerts.
Recent news
November 7, 2026
Study Links Anaphylaxis Reactions to Suspected CofactorsAnalysis of 16,915 European registry cases finds suspected cofactors in nearly half of reactions, with patterns differing between children and adults.
November 6, 2026
PAHO Issues Measles Advice Ahead of Papal VisitThe Pan American Health Organization urges travellers and pilgrims to take measles precautions as Pope Leo XIV tours Latin America.
November 6, 2026
PAHO Launches Malaria Elimination Plan for AmericasThe 2026-2030 action plan targets a 50 per cent cut in malaria incidence by 2030 compared with 2024 levels.
November 5, 2026
Mabylon Study Links IgG4 Antibodies to Allergy ToleranceResearchers report allergen-specific IgG4 antibodies redirect allergens toward immune cells that promote tolerance-associated responses.
November 5, 2026
Dutch Pharmacy Compounds Tiratricol for Indian ChildrenA low-cost compounded version of a rare-disease thyroid drug is being made for seven children in India after its commercial price rose sharply.
November 3, 2026
Telitacicept Slows Kidney Decline in IgA NephropathyA phase 3 trial found the drug reduced proteinuria and stabilized kidney function over two years compared with placebo.
November 3, 2026
Nineteen Football Fans Treated for Suspected PoisoningParticipants in the Dostlik Cup 2026 festival from Karaganda sought medical help in Tashkent, Uzbekistan.
November 2, 2026
Study Finds Stigma Common in Children With VitiligoResearchers report that stigma affects many children with vitiligo, including those with mild-to-moderate disease, and is linked to depression and anxiety.
November 2, 2026
Deucrictibant Speeds Relief in Hereditary Angioedema TrialA phase 3 trial found the immediate-release capsule relieved symptoms of hereditary angioedema attacks faster than placebo.
November 2, 2026
Travelers Risk Voided Policies by Withholding Medical HistoryA 2026 AllClear Travel Insurance report finds many travelers with pre-existing conditions do not realize non-disclosure invalidates their coverage.
More in Allergies
Reporting here centers on clinical studies, food safety standards, medication approvals and seasonal management trends. Global reporting spans every region and institution where these conditions are studied or managed. The interplay between climate patterns and airborne triggers remains a primary driver of seasonal health data. Research into prevalence and immunotherapy shifts the focus as new findings reach the scientific community.